We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00170170
First Posted: September 15, 2005
Last Update Posted: February 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Roche Pharma AG
Information provided by:
Mayo Clinic
  Purpose
This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.

Condition
Transplantation Infection Cytomegalovirus Infections

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Enrollment: 500
Study Start Date: November 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:
This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Recipients of liver, kidney, pancreas, heart or lung transplantation
Criteria

Inclusion Criteria:

  • Recipients of liver, kidney, pancreas, heart or lung transplantation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170170


Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Roche Pharma AG
Investigators
Principal Investigator: Raymund R. Razonable, M.D. Mayo Clinic
  More Information

ClinicalTrials.gov Identifier: NCT00170170     History of Changes
Other Study ID Numbers: 2275-04
VAL101
First Submitted: September 13, 2005
First Posted: September 15, 2005
Last Update Posted: February 2, 2010
Last Verified: February 2010

Keywords provided by Mayo Clinic:
cytomegalovirus

Additional relevant MeSH terms:
Infection
Communicable Diseases
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases